• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Vaccines Against Shigella and Enterotoxigenic Escherichia coli:A summary of the 2018 VASE Conference
【24h】

Vaccines Against Shigella and Enterotoxigenic Escherichia coli:A summary of the 2018 VASE Conference

机译：针对志贺氏菌和肠毒素大肠杆菌的疫苗：2018年花瓶会议的摘要

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PATH hosted the second Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference in Mexico City in June 2018, again providing experts from around the world an opportunity to participate in a highly collaborative forum to discussprogress in the development of new enteric vaccines. Through a combination of plenary sessions and posters, keynote presentations, and workshops, the 2018 VASE Conference aimed to accelerate communication and progress among those working to achieve thegoal of licensed vaccines against these two bacterial pathogens. Many presentations recognized the importance of diarrheal disease and long-term sequelae caused by infections with Shigella and enterotoxigenic E. coli (ETEC). Other presentations explorednew strategies for vaccine development, including the search for novel, possibly conserved, antigens for more effective vaccines. Much progress is being made as some vaccine candidates are now moving through clinical trials. Research presented in oral and poster presentations at the VASE Conference covered a range of topics, including: the global burden of disease, epidemiology, and health economics; host parameters and genomics that predict responses to infection and disease; preclinical evaluations ofvaccine antigens and models of enteric diseases; and vaccine candidates in clinical trials and human challenge studies. This article reviews key points and highlighted research presented in each of the plenary conference sessions and poster presentations at the 2018 VASE Conference.
机译：PATH托管在墨西哥城第二次疫苗抗痢疾杆菌毒素大肠杆菌（花瓶）会议2018年6月，再次提供专家来自世界各地的有机会参加在高度协作论坛discussprogress在新的肠疫苗的开发。通过全体会议和海报的组合，主题演讲和研讨会，2018年的花式会议旨在加速沟通和进展，以实现持续持续疫苗的持续持有的两种细菌病原体。许多演示文献认识到腹泻病和长期后遗症的感染引起的感染和肠毒素大肠杆菌（ETEC）的重要性。其他演示探讨了疫苗开发的策略，包括寻找新颖，可能保守的抗原以获得更有效的疫苗。随着一些疫苗候选人现在正在通过临床试验，正在进行大量进展。在VASE会议上的口头和海报演示中提出的研究涵盖了一系列主题，包括：全球疾病，流行病学和健康经济学负担;宿主参数和基因组学，其预测对感染和疾病的反应;对抗原和肠疾病模型的临床前评估;临床试验和人类挑战研究中的疫苗候选者。本文审查了2018年“花瓶会议上的每个全体会议会议和海报演示”中提出的重点和突出显示的研究。

著录项

  • 来源
    《Vaccine》 |2019年第34期|共7页
  • 作者

    Eileen Barry; Fred Cassels; Mark Riddle;

  • 作者单位

    Center for Vaccine Development and Global Health University of Maryland School of Medicine Baltimore MD USA;

    PATH 4555 Massachusetts Ave NW Washington DC USA;

    Department of Preventive Medicine and Biostatistics Uniformed Services University of the Health Sciences Bethesda MD USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 医学免疫学;
  • 关键词

    Diarrhea; Stunting; ETEC; Shigella; Immunization; Vaccines;

    机译：腹泻;衰退;ETEC;志贺氏;免疫;疫苗;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号